https://www.selleckchem.com/products/OSI-906.html
Triheptanoin provides long-chain fatty acid oxidation disorder (LC-FAOD) patients with an alternative to medium-even-chain triglycerides therapy. Retrospective analysis of 18 French LC-FAOD patients benefiting from early access to triheptanoin treatment. Eight female and 10 male patients with LC-FAOD (VLCAD, LCHAD, CACT, CPTII and MTP) were treated with triheptanoin for a median duration of 22months (range 9-228months). At last consultation, triheptanoin accounted for 15-35% of their daily caloric intake. In the year following the intro